SMA Capital’s Royalty Pharma RPRX Stock Holding History

SMA Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-481	Closed	-$23.1K	–	164
2026 Q1	$23.1K	Buy	+481	New	+$21.1K	0.01%	44

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SMA Capital's RPRX Position: Q2 2026 in Review

SMA Capital sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 481 shares — an estimated $23.1K sold.

SMA Capital first reported a position in RPRX in Q1 2026 and held it in 1 quarter. The position peaked at $23.1K in Q1 2026. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

SMA Capital reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
SMA Capital sold 481 Royalty Pharma shares in Q2 2026, an estimated $23.1K.
SMA Capital first reported a position in Royalty Pharma in Q1 2026 and held it in 1 quarter.
SMA Capital's Royalty Pharma position peaked at $23.1K in Q1 2026.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.